

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A method for propagating replication-defective adenovirus in an adenoviral E1-complementing cell line where the adenoviral E1-complementing cell line expresses an E1 gene product(s) which is not of the same serotype as the replication-defective adenovirus, which comprises:

(a) inserting all or a portion of a heterologous adenoviral E4 region comprising a nucleic acid sequence encoding open reading frame 6 (ORF6) into a replication-defective adenovirus; wherein the E4 region or portion thereof is of the same adenovirus serotype as the E1 gene product(s) expressed by the complementing cell line;

(b) introducing the replication-defective adenovirus into the adenoviral E1-complementing cell line;

(c) allowing the replication-defective adenovirus to propagate in the adenoviral E1-complementing cell line; and

(d) rescuing the propagated adenovirus,

wherein the heterologous adenoviral E4 region or portion thereof is inserted into the replication-defective adenovirus in place of nucleic acid sequence encoding open reading frame 6 (ORF6) or nucleic acid sequence encoding the complete adenoviral E4-encoding region.

2. (previously presented) The method of claim 1 wherein the heterologous adenoviral E4 region or portion thereof comprises the complete adenoviral E4-encoding region.

3. (previously presented) The method of claim 2 wherein the heterologous adenoviral E4 region or portion thereof comprises the complete adenoviral E4-encoding region and native E4 promoter.

4. (previously presented) The method of claim 1 wherein the heterologous adenoviral E4 region or portion thereof is inserted into the replication-defective adenovirus in place of nucleic acid sequence encoding open reading frame 6 (ORF6).

5. (previously presented) The method of claim 1 wherein the heterologous adenoviral E4 region or portion thereof is inserted into the replication-defective adenovirus in place of nucleic acid sequence encoding the complete adenoviral E4-encoding region.
6. (previously presented) The method of claim 1 wherein the heterologous adenoviral E4 region or portion thereof is derived from a subgroup C adenovirus.
- 7 (previously presented) The method of claim 6 wherein the subgroup C adenovirus is adenovirus of serotype 5.
8. (previously presented) The method of claim 7 wherein the replication-defective adenovirus is an adenovirus of subgroup B.
9. (previously presented) The method of claim 7 wherein the replication-defective adenovirus is an adenovirus of serotype 35.
10. (previously presented) The method of claim 1 wherein the heterologous adenoviral E4 region or portion thereof is operatively linked to a heterologous promoter.
11. (previously presented) The method of claim 1 wherein the adenoviral E1-complementing cell line is a PER.C6® cell line.
- 12-20. (canceled)
21. (previously presented) The method of claim 1 wherein the replication-defective adenovirus comprises a heterologous gene of interest.
22. (previously presented) The method of claim 21 wherein the heterologous gene of interest is a gene encoding an HIV-1 antigen.
23. (previously presented) The method of claim 22 wherein the HIV-1 antigen is selected from the group consisting of: HIV-1 gag, pol, nef and env.
- 24-83. (canceled)
84. (new) The method of claim 21 wherein the heterologous gene of interest is inserted into an E1-deleted region.